Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study

被引：0
作者：
Di Wu
Peng Wang
Meifang Han
Yongping Chen
Xinyue Chen
Qi Xia
Weiming Yan
Xiaoyang Wan
Chuanlong Zhu
Qing Xie
Jiaji Jiang
Lai Wei
Deming Tan
Xiaoguang Dou
Yanyan Yu
Jinlin Hou
Xiaoping Luo
Qin Ning
机构：
[1] Huazhong University of Science and Technology,Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College
[2] The First Affiliated Hospital of Wenzhou Medical University,Department of Infectious Disease
[3] Capital Medical University,International Medical Department, Beijing You’an Hospital
[4] Zhejiang University,State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine
[5] Anhui Medical University,Department of Infectious Disease, Anhui Provincial Hospital
[6] Jiaotong University School of Medicine,Department of Infectious Diseases, Shanghai Ruijin Hospital
[7] First Affiliated Hospital of Fujian Medical University,Liver Research Center
[8] Peking University People’s Hospital,Department of Hepatology
[9] Central South University,Department of Infectious Diseases, Xiangya Hospital
[10] Shengjing Hospital of China Medical University,Department of Infectious Disease
[11] Peking University First Hospital,Department of Infectious Diseases
[12] Southern Medical University,Department of Infectious Diseases, Nanfang Hospital
[13] Huazhong University of Science and Technology,Department of Pediatrics, Tongji Hospital, Tongji Medical College
来源：
Hepatology International | 2019年 / 13卷
关键词：
Hepatitis B surface antigen loss; Interferon; Entecavir; Combination therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：573 / 586
页数：13
相关论文
共 266 条
[1]  
Dandri M(2012)New insight in the pathobiology of hepatitis B virus infection Gut 61 i6-i17
[2]  
Locarnini S(2002)Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection Gastroenterology 123 1084-1089
[3]  
Chen YC(2008)Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b Gastroenterology 135 459-467
[4]  
Sheen IS(2009)High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study J Hepatol 50 1084-1092
[5]  
Chu CM(2017)Clinical Practice Guidelines on the management of hepatitis B virus infection J Hepatol 2017 370-398
[6]  
Liaw YF(2016)Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update Hepatol Int 10 1-98
[7]  
Buster EH(2016)AASLD guidelines for treatment of chronic hepatitis B Hepatology 63 261-283
[8]  
Flink HJ(2005)Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2682-2695
[9]  
Cakaloglu Y(2004)Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 1206-1217
[10]  
Simon K(2010)Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 422-430
12345678910